公开(公告)号：US20170022222A1

公开(公告)日：2017-01-26

申请号：US15289650

申请日：2016-10-10

申请人： Takeda Pharmaceutical Company Limited

发明人： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC分类号： C07D513/04

CPC分类号： C07D513/04

摘要： Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

摘要翻译： 其中每个符号如说明书中所定义，或其盐，其具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体增强作用。 本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。

公开(公告)号：US20150073137A1

公开(公告)日：2015-03-12

申请号：US14540699

申请日：2014-11-13

申请人： Takeda Pharmaceutical Company Limited

发明人： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC分类号： C07D513/04

CPC分类号： C07D513/04

摘要： Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20190263832A1

公开(公告)日：2019-08-29

申请号：US16256773

申请日：2019-01-24

申请人： Takeda Pharmaceutical Company Limited

发明人： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC分类号： C07D513/04

摘要： Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20170121308A1

公开(公告)日：2017-05-04

申请号：US15318552

申请日：2015-06-11

申请人： Takeda Pharmaceutical Company Limited

发明人： Masaki OGINO ,  Eiji KIMURA ,  Shinkichi SUZUKI ,  Tomoko ASHIZAWA ,  Toshihiro IMAEDA ,  Ikuo FUJIMORI ,  Ryosuke ARAI

IPC分类号： C07D401/10 ,  C07D213/81 ,  C07D405/14

CPC分类号： C07D401/10 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  C07D213/81 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14

摘要： The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

公开(公告)号：US20160264536A1

公开(公告)日：2016-09-15

申请号：US15031505

申请日：2014-10-22

申请人： Takeda Pharmaceutical Company Limited

发明人： Masaki SETO ,  Yoshihiro BANNO ,  Toshihiro IMAEDA ,  Yuichi KAJITA ,  Tomoko ASHIZAWA ,  Masanori KAWASAKI ,  Shinji NAKAMURA ,  Satoshi MIKAMI ,  Izumi NOMURA ,  Takahiko TANIGUCHI ,  Shogo MARUI

IPC分类号： C07D277/56 ,  C07D403/12 ,  C07D239/28 ,  C07D403/04 ,  C07D239/47 ,  C07D239/36 ,  C07D239/52 ,  C07D241/24 ,  C07D498/08 ,  C07D413/04 ,  C07D405/04 ,  C07D401/04 ,  C07D417/04 ,  C07D409/04 ,  C07D401/12 ,  C07D239/42

CPC分类号： C07D277/56 ,  C07D239/28 ,  C07D239/36 ,  C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D239/52 ,  C07D239/54 ,  C07D239/56 ,  C07D241/24 ,  C07D241/26 ,  C07D277/20 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D498/04 ,  C07D498/08

摘要： The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

摘要翻译： 其中每个符号如说明书中所述或其盐。

公开(公告)号：US20240360156A1

公开(公告)日：2024-10-31

申请号：US18592897

申请日：2024-03-01

申请人： Takeda Pharmaceutical Company Limited

发明人： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC分类号： C07D513/04

CPC分类号： C07D513/04

摘要： Provided is a compound represented by the formula (I):




wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20230357220A1

公开(公告)日：2023-11-09

申请号：US17999514

申请日：2021-05-20

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Tomoaki HASUI ,  Satoshi MIKAMI, JR. ,  Toru YAMASHITA ,  Shinji NAKAMURA ,  Shinji MORIMOTO ,  Toshihiro IMAEDA ,  Kazuaki TAKAMI ,  Masaki DAINI ,  Hiroyuki KAKEI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Chunxiang WANG ,  Sachie TAKASHIMA ,  Makoto KAMATA ,  Yuya OGURO ,  Shuhei IKEDA

IPC分类号： C07D413/14 ,  C07D405/14 ,  C07D401/14

CPC分类号： C07D413/14 ,  C07D401/14 ,  C07D405/14

摘要： Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer’s disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

公开(公告)号：US20200317692A1

公开(公告)日：2020-10-08

申请号：US16827316

申请日：2020-03-23

申请人： Takeda Pharmaceutical Company Limited

发明人： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC分类号： C07D513/04

摘要： Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20180162875A1

公开(公告)日：2018-06-14

申请号：US15845621

申请日：2017-12-18

申请人： Takeda Pharmaceutical Company Limited

发明人： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC分类号： C07D513/04

CPC分类号： C07D513/04

摘要： Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20180155333A1

公开(公告)日：2018-06-07

申请号：US15568644

申请日：2016-04-22

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Taku KAMEI ,  Yasuyoshi ARIKAWA ,  Tomohiro OHASHI ,  Toshihiro IMAEDA ,  Ikuo FUJIMORI ,  Takashi MIKI ,  Jinichi YONEMORI ,  Yuya OGURO ,  Takahiro SUGIMOTO ,  Masaki SETO ,  Goushi NISHIDA ,  Makoto KAMATA ,  Hiroshi IMOTO

IPC分类号： C07D413/14 ,  C07D413/04 ,  C07D417/14 ,  C07D409/14 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30

CPC分类号： C07D413/14 ,  A61K31/553 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C07D409/14 ,  C07D413/04 ,  C07D417/14

摘要： The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.